A New Biological Front in MS: Fenebrutinib For Primary Progressive Multiple Sclerosis (PPMS)

from TheBrief.Health · host TheBrief.Health

Fenebrutinib, an oral BTK inhibitor, shows non-inferiority to ocrelizumab in PPMS, targeting CNS inflammation, reducing infusion burden, and expanding equitable, scalable progressive multiple sclerosis care.

Episode metadata supplied by the publisher feed · Published Apr 3, 2026

Embed this episode

Attribution link and audio player

NOW PLAYING

A New Biological Front in MS: Fenebrutinib For Primary Progressive Multiple Sclerosis (PPMS)

0:00 1:58

1×

No transcript for this episode yet

We transcribe on demand. Request one and we'll notify you when it's ready — usually under 10 minutes.

Share this episode

Similar Episodes

No similar episodes found.

Similar Podcasts

No similar podcasts found.

Frequently Asked Questions

How long is this episode of TheBrief.Health?

This episode is 1 minute long.

When was this TheBrief.Health episode published?

This episode was published on April 3, 2026.

Can I download this TheBrief.Health episode?

Yes. Use the download control on the episode player to save the publisher-provided media file.

URL copied to clipboard!